Evidence map›Paper›PMID 34944839›Full record

ArticleCancers2021

Characterization of Genetic Heterogeneity in Recurrent Metastases of Renal Cell Carcinoma.

Carolin Sauter-Meyerhoff, Regina Bohnert, Pascale Mazzola, Viktoria Stühler, Siarhei Kandabarau, Florian A Büttner, Stefan Winter, Lisa Herrmann, Steffen Rausch, Jörg Hennenlotter and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Carolin Sauter-MeyerhoffDr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, 70376 Stuttgart, Germany.ORCID 0000-0001-9348-9121
Regina BohnertDr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, 70376 Stuttgart, Germany.
Pascale MazzolaDr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, 70376 Stuttgart, Germany.
Viktoria StühlerDepartment of Urology, University Hospital Tuebingen, 72076 Tuebingen, Germany.
Siarhei KandabarauDr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, 70376 Stuttgart, Germany.
Florian A BüttnerDr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, 70376 Stuttgart, Germany.ORCID 0000-0002-0657-9522
Stefan WinterDr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, 70376 Stuttgart, Germany.
Lisa HerrmannDepartment of Urology, University Hospital Tuebingen, 72076 Tuebingen, Germany.
Steffen RauschDepartment of Urology, University Hospital Tuebingen, 72076 Tuebingen, Germany.ORCID 0000-0002-6398-8701
Jörg HennenlotterDepartment of Urology, University Hospital Tuebingen, 72076 Tuebingen, Germany.ORCID 0000-0003-3827-6996
Falko FendInstitute of Pathology and Neuropathology, University Hospital Tuebingen, 72076 Tuebingen, Germany.
Marcus ScharpfInstitute of Pathology and Neuropathology, University Hospital Tuebingen, 72076 Tuebingen, Germany.
Arnulf StenzlDepartment of Urology, University Hospital Tuebingen, 72076 Tuebingen, Germany.ORCID 0000-0003-4207-9928
Stephan OssowskiInstitute of Medical Genetics and Applied Genomics, University of Tuebingen, 72076 Tuebingen, Germany.
Jens BedkeDepartment of Urology, University Hospital Tuebingen, 72076 Tuebingen, Germany.ORCID 0000-0003-2778-3108
Matthias SchwabDr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, 70376 Stuttgart, Germany.
Elke SchaeffelerDr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, 70376 Stuttgart, Germany.
Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology · DEGerman Cancer Research Center · DEUniversity of Tübingen · DE

Funding

Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy EXC 2180 - 390900677Horizon 2020-PHC-2015 U-PGx 668353ICEPHA Graduate School Tuebingen-Stuttgart NAIZKF Program of the Medical Faculty Tuebingen NARobert Bosch Stiftung (Stuttgart, Germany) NA
6 · The paper itself

Abstract

Metastatic renal cell carcinoma (RCC) exhibits poor prognosis. Better knowledge of distant metastases is crucial to foster personalized treatment strategies. Here, we aimed to investigate the genetic landscape of metastases, including synchronous and/or recurrent metastases to elucidate potential drug target genes and clinically relevant mutations in a real-world setting of patients. We assessed 81 metastases from 56 RCC patients, including synchronous and/or recurrent metastases of 19 patients. Samples were analysed through next-generation sequencing with a high coverage (~1000× mean coverage). We therefore established a novel sequencing panel comprising 32 genes with impact on RCC development. We observed a high frequency of mutations in known RCC driver genes (e.g., >40% carriers of

Indexed as

metastasisnext-generation sequencingpersonalized therapypharmacogenomicsrenal cell carcinoma

Identifiers

PMID34944839
PMCPMC8699544
OpenAlexW4200286947

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.